Key result
LY294002 selectively inhibits IKur at substantially lower concentrations, indicating potential as a targeted cardiac blocker.
Why the study?
Current antiarrhythmic pharmacotherapies for atrial fibrillation have limited efficacy and carry risks of off-target ventricular block, making it uncertain whether the Kv1.5 inhibitor LY294002 exhibits functional selectivity for I Kur over major counter-target cardiac ion currents.
LY294002 demonstrates relative functional selectivity for the atrial-specific IKur channel over other major cardiac ion channels, supporting its potential as a structural scaffold for developing atrium-selective antiarrhythmic agents.
Should not yet change arrhythmia management; leaves open selective IKur targeting for further preclinical validation.
Background and purpose Atrial fibrillation (AF) is the most prevalent clinical arrhythmia, yet current antiarrhythmic pharmacotherapies have limited efficacy and pose risks of off-target ventricular block. LY294002 was reported to inhibit the ultrarapid delayed-rectifier potassium current ( I Kur ) carried by Kv1.5 channels, a promising atrium-selective therapeutic target for AF. To determine whether LY294002 exhibits functional selectivity for I Kur , this study comprehensively examined its inhibitory effects on major counter-target cardiac ion currents. Methods The cDNAs encoding the principal pore-forming subunits of major cardiac channels—mediating I Kr (Kv11.1), I Ks (Kv7.1), I K1 (Kir2.1), I to (Kv4.3), I Na (Nav1.5), and I Ca-L (Cav1.2)—were heterologously expressed in Chinese hamster ovary cells. The inhibitory effects of LY294002 on these channels were assessed using the whole-cell patch-clamp technique. Furthermore, molecular docking analysis was conducted to characterize the structural interactions and binding configurations of LY294002 with Kv1.5. Results LY294002 inhibited all investigated currents in a concentration-dependent manner, albeit with markedly varying potencies. Based on Hill equation fits, the half-maximal inhibitory concentration (IC 50 ) values for LY294002 on I Ks , I Kr , I to , I K1 , I Na , and I Ca-L were 21.5, 26.3, 55.9, 81.5, 131.6, and 46.5 μM, respectively. Notably, the lowest off-target IC 50 ( I Ks ) was approximately 2.7-fold higher than the previously reported IC 50 for I Kur (7.9 μM). Molecular docking analysis revealed that LY294002 bound within the internal cavity of Kv1.5, with predicted binding affinity of −8.3 kcal I mol −1 . Conclusion The inhibitory potency of LY294002 against I Kur is substantially higher than its potency against other major cardiac currents, demonstrating its potential to act as a selective I Kur blocker. Structurally, this preferential inhibition is likely mediated by the compound’s favorable occupancy of key gating or pore regions unique to the Kv1.5 channel conformation.
No takes yet. Share an insight, caveat, or question.
Niu et al. (2026) studied Atrial fibrillation. LY294002 vs. Baseline was evaluated on Half-maximal inhibitory concentration (IC50) on major cardiac ion channels. LY294002 inhibited major cardiac ion currents at IC50 values of 21.5-131.6 µM, which are substantially higher than its IC50 for IKur (7.9 µM), indicating its potential as a selective IKur blocker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: